Drugs / sulfadoxine-pyrimethamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00126906 | Oct 2002 → Mar 2005 | HIV infectious disease, Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-08-26 | Halcygen Pharmaceuticals Limited | Regulatory First African-manufactured medicine to prevent malaria in pregnant women and infants quality - approved by WHO strides.com ↗
Universal Corporation Ltd (UCL), with support from MMV and Unitaid, becomes the first African manufacturer to gain WHO prequalification of sulfadoxine-pyrimethamine |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-26 | Halcygen Pharmaceuticals Limited | First African-manufactured medicine to prevent malaria in pregnant women and infants quality - approved by WHO strides.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sulfadoxine-pyrimethamine | “Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitemia and associated maternal anemia, premature...” PMID 16826475 ↗ Jun 2006 |